Roivant Sciences Officer Eric Venker Sells $7.0M in Common Shares Under 10b5-1 Plan

Insider Transaction Overview

On October 20, 2026, Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. ($ROIV), executed sales totaling 200,000 common shares across two transactions:

• Tranche 1: 185,856 shares sold at a weighted-average price of $35.09 (range: $34.38 to $35.38)
• Tranche 2: 14,144 shares sold at a weighted-average price of $35.42 (range: $35.39 to $35.51)

The aggregate gross proceeds totaled approximately $7,022,688 at an average realization price of ~$35.11 per share.

Ownership Impact

• Prior Direct Holdings: 1,599,154 shares
• Shares Sold: 200,000 shares (~12.5% reduction in direct holdings)
• Post-Transaction Holdings: 1,399,154 shares

Context and Trading Plan

Both transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2026. Because the sales were scheduled via a 10b5-1 plan established nearly four months prior, they reflect automated execution rather than discretionary, market-timed selling. Even following the sale, Dr. Venker maintains a substantial direct equity position of nearly 1.4 million shares.